Official Title
DisCOVEries 2 - An Observational Study to Evaluate the Immunogenicity of mRNA COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
Brief Summary

The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).

Detailed Description

Not Provided

Active, not recruiting
COVID-19

Biological: Moderna COVID-19 Vaccine

Sterile liquid for injection. Intervention not administered through this study.

Biological: Moderna mRNA1273.222 Booster

Sterile liquid for injection. Intervention not administered through this study.

Biological: Pfizer COVID-19 Vaccine

Sterile liquid for injection. Intervention not administered through this study.

Biological: Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)

Sterile liquid for injection. Intervention not administered through this study.

Biological: Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)

Sterile liquid for injection. Intervention not administered through this study.

Eligibility Criteria

Inclusion Criteria:

- Lives in the continental United States (US).

- Speaks, reads, and understands English.

- Is willing and able to submit vaccination card photo(s) or vaccination records.

- Is willing and able to self-collect capillary blood during the study period via an
at-home whole-blood collection device.

- Is fully vaccinated against COVID-19 per protocol specified criteria.

Exclusion Criteria:

- Has been diagnosed with significant cognitive impairment or dementia.

- Is pregnant or planning to become pregnant during the study period.

- Primary mailing address is a Post Office box, Army Post Office, Fleet Post Office, or
Diplomatic Post Office address.

- Currently lives in a US military base located overseas, or US territories (Puerto
Rico, US Virgin Islands, Guam, Northern Mariana Island, or American Samoa).

- Is currently participating in a COVID-19 vaccine clinical trial.

- Is currently receiving chemotherapy or has received chemotherapy in the past 6 months.

- Is currently taking steroids, such as prednisone, for any condition.

- Has been diagnosed with and taking immunosuppressants for rheumatoid arthritis, lupus
or multiple sclerosis.

- Has received an organ transplant.

- Is currently undergoing dialysis of any kind (for example, hemodialysis or chronic
ambulatory dialysis) for kidney disease.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Science37
Culver City, California, United States

Not Provided

ModernaTX, Inc.
NCT Number
Keywords
Immunogenicity
Moderna
mRNA-1273
Omicron
Vaccines
MeSH Terms
COVID-19
Vaccines